Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 1:17 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT04191499
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Placebo, Palbociclib, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Beverly Hills, California • Boston, Massachusetts • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 1:17 AM EDT
Enrolling by invitation Not applicable Interventional

Essential Amino Acid Supplementation in Adult Spinal Deformity Patients

NCT07341399
View directory record Official record
Conditions
Adult Spinal Deformity
Interventions
Essential Amino Acid Supplement by Amino Co, Placebo
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

NCT04173819
View directory record Official record
Conditions
HIV-1-infection
Interventions
3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 45 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Not applicable Interventional Results available

Study of the Effect of the Drug Gabapentin on Postoperative Pain and Incidence of Postoperative Nausea and Vomiting

NCT00886236
View directory record Official record
Conditions
Obesity, Morbid, Postoperative Pain, Postoperative Nausea and Vomiting
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 31, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

NCT04899271
View directory record Official record
Conditions
New-onset Type 1 Diabetes
Interventions
Ladarixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Minocycline to Treat Central Retinal Vein Occlusion

NCT01468844
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Minocycline, Placebo, Bevacizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

NCT00044044
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

NCT00880334
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Cancer
Interventions
Docetaxel, vandetanib, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

NCT01752634
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
21
States / cities
Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 31, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional

Pilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury

NCT06109909
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Photophobia
Interventions
Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

NCT00289198
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FF, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
8
States / cities
San Diego, California • Baltimore, Maryland • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

NCT00076063
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP1452), LIPO-5
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health

NCT02999230
View directory record Official record
Conditions
Dental Caries
Interventions
Caries Free 1.5% Arginine, Caries Free Placebo Sodium Fluoride, Caries Active 1.5% Arginine, Caries Active- Placebo Sodium Fluoride
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain

NCT00899600
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Ketamine, Normal saline
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 31, 2026, 1:17 AM EDT
Recruiting Phase 2 Interventional

Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial

NCT04944836
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Clomiphene Citrate, Rotator Cuff Repair
Drug · Procedure
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

NCT01508936
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)

NCT01936844
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra (high dose), Anakinra (standard dose), Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 31, 2026, 1:17 AM EDT
Withdrawn Phase 4 Interventional

L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD

NCT01855334
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Spironolactone, L-arginine, Placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

NCT02822599
View directory record Official record
Conditions
Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
Interventions
RiaStAP, Saline
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
1 Day to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 31, 2026, 1:17 AM EDT
Completed Phase 2Phase 3 Interventional

Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder

NCT00873509
View directory record Official record
Conditions
Autistic Disorder
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Chugani, Diane C.
Individual
Eligibility
2 Years to 6 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Sacramento, California • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 31, 2026, 1:17 AM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 1:17 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo
Drug · Biological
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
La Jolla, California • Orange, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 1:17 AM EDT
Terminated Phase 3 Interventional Results available

Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females

NCT00575328
View directory record Official record
Conditions
Sexual Dysfunction, Bipolar Disorder
Interventions
Maca Root, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 31, 2026, 1:17 AM EDT